Sandoz: biosimilar targets inflammatory diseases
(CercleFinance.com) - On Thursday, Sandoz announced the European launch of Pyzchiva, a biosimilar version of the inflammatory disease drug ustekinumab originally developed by Samsung Bioepis.
The Swiss laboratory explains that Pyzchiva is indicated for the treatment of all conditions covered by the reference drug, namely plaque psoriasis, psoriatic arthritis, Crohn's disease and plaque psoriasis in pediatric patients aged over six and weighing over 60 kg.
Sandoz points out that Europe has the highest prevalence of psoriasis in the world, with 6.4 million people affected.
Last September, Sandoz signed an agreement with Samsung Bioepis giving it the right to market a generic version of ustekinumab in the United States, Canada, Europe, the United Kingdom and Switzerland.
Under the terms of the agreement, Samsung Bioepis remains responsible for the intellectual property, manufacturing and supply of the monoclonal antibody.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Swiss laboratory explains that Pyzchiva is indicated for the treatment of all conditions covered by the reference drug, namely plaque psoriasis, psoriatic arthritis, Crohn's disease and plaque psoriasis in pediatric patients aged over six and weighing over 60 kg.
Sandoz points out that Europe has the highest prevalence of psoriasis in the world, with 6.4 million people affected.
Last September, Sandoz signed an agreement with Samsung Bioepis giving it the right to market a generic version of ustekinumab in the United States, Canada, Europe, the United Kingdom and Switzerland.
Under the terms of the agreement, Samsung Bioepis remains responsible for the intellectual property, manufacturing and supply of the monoclonal antibody.
Copyright (c) 2024 CercleFinance.com. All rights reserved.